#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	12726	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2046	617.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1371	1371	C	732	C	660	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	12726	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2046	617.5	0	HET	.	.	.	C575T	.	575	575	C	762	762	C	742	C,T	580,85	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	12726	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2046	617.5	0	HET	.	.	.	A109G	.	109	109	A	296	296	A	745	A,G	550,112	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23098	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3483	660.8	0	.	n	.	0	T695C	SNP	695	695	T	971	971	C	656	C,T	600,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23098	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3483	660.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1613	1613	A	809	A	722	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23098	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3483	660.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2247	2247	C	788	C	695	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23098	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3483	660.8	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2873	2873	T	726	T,C	479,177	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23098	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3483	660.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2321	2321	A	796	A,T	714,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23098	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3483	660.8	0	HET	.	.	.	C2632T	.	2632	2632	C	2908	2908	C	752	C,T	479,181	.	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	155	1860	folP	852	852	100.0	folP.l15.c17.ctg.1	1370	134.1	1	SNP	p	R228S	1	.	.	682	684	AGC	912	914	AGC	179;179;179	A;G;C	162;161;160	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	155	1860	folP	852	852	100.0	folP.l15.c17.ctg.1	1370	134.1	0	HET	.	.	.	A694G	.	694	694	A	924	924	A	177	A,G	123,37	.	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	155	1860	folP	852	852	100.0	folP.l15.c17.ctg.1	1370	134.1	0	HET	.	.	.	C225CGAAGAAGAA,CGAAGAAGAAGAA	.	225	225	C	455	455	C	183	CGAAGAAGAA,CGAAGAAGAAGAA	125,34	.	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	155	1860	folP	852	852	100.0	folP.l15.c17.ctg.1	1370	134.1	0	HET	.	.	.	T202C	.	202	202	T	432	432	T	179	T,C	116,32	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	155	4874	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3231	150.3	1	SNP	p	S91F	0	.	.	271	273	TCC	543	545	TCC	168;168;171	T;C;C	157;156;159	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	155	4874	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3231	150.3	1	SNP	p	D95N	0	.	.	283	285	GAC	555	557	GAC	168;167;169	G;A;C	155;156;158	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	155	4874	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3231	150.3	1	SNP	p	D95G	0	.	.	283	285	GAC	555	557	GAC	168;167;169	G;A;C	155;156;158	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	155	1408	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1070	129.1	1	SNP	p	G45D	1	.	.	133	135	GAC	353	355	GAC	177;177;181	G;A,G;C	156;104,47;156	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	155	1408	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1070	129.1	0	HET	.	.	.	A360G	.	360	360	A	580	580	A	195	A,G	132,39	.	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	155	1408	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1070	129.1	0	HET	.	.	.	G115A	.	115	115	G	335	335	G	169	G,A	106,47	.	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	155	1408	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1070	129.1	0	HET	.	.	.	C87G	.	87	87	C	307	307	C	178	C,G	118,38	.	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	155	1408	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1070	129.1	0	HET	.	.	.	G345A	.	345	345	G	565	565	G	196	G,A	136,35	.	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	155	1408	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1070	129.1	0	HET	.	.	.	C90T	.	90	90	C	310	310	C	172	C,T	113,38	.	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	155	1408	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1070	129.1	0	HET	.	.	.	T354C	.	354	354	T	574	574	T	188	T,C	125,37	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	147	708	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1001	70.3	0	HET	.	.	.	C45T	.	45	45	C	411	411	C	189	C,T	130,43	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	155	5090	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2958	171.6	1	SNP	p	D86N	0	.	.	256	258	GAC	618	620	GAC	208;204;204	G,T;A;C	185,1;180;183	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	155	5090	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2958	171.6	1	SNP	p	S87R	0	.	.	259	261	AGT	621	623	AGT	203;201;197	A;G;T	181;182;177	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	155	5090	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2958	171.6	1	SNP	p	S87I	0	.	.	259	261	AGT	621	623	AGT	203;201;197	A;G;T	181;182;177	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	155	5090	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2958	171.6	1	SNP	p	S87W	0	.	.	259	261	AGT	621	623	AGT	203;201;197	A;G;T	181;182;177	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	155	5090	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2958	171.6	1	SNP	p	S88P	0	.	.	262	264	TCC	624	626	TCC	196;196;197	T;C;C	174;175;176	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	155	5090	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2958	171.6	0	HET	.	.	.	C1431T	.	1431	1431	C	1793	1793	C	220	C,T	149,55	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	155	5090	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2958	171.6	0	HET	.	.	.	T1304C	.	1304	1304	T	1666	1666	T	203	T,C	123,49	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	155	5090	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2958	171.6	0	HET	.	.	.	G1305A	.	1305	1305	G	1667	1667	G	205	G,A	133,47	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	155	5090	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2958	171.6	0	HET	.	.	.	G1786A	.	1786	1786	G	2148	2148	G	214	G,A	131,51	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	155	5090	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2958	171.6	0	HET	.	.	.	C1435T	.	1435	1435	C	1797	1797	C	222	C,T	152,55	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	155	5090	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2958	171.6	0	HET	.	.	.	G1150A	.	1150	1150	G	1512	1512	G	215	G,A	143,44	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	155	5090	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2958	171.6	0	HET	.	.	.	C990G	.	990	990	C	1352	1352	C	194	C,G	138,38	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	155	5090	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2958	171.6	0	HET	.	.	.	A1326G	.	1326	1326	A	1688	1688	A	211	A,G	138,50	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4072	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2434	166.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1470	1472	GGC	184;183;183	G;G;C	168;169;165	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	667	3632	penA	1749	1749	99.09	penA.l6.c30.ctg.1	2212	163.2	0	.	p	.	0	C41G	NONSYN	121	123	TGT	403	405	GGT	167;166;166	G,T;G;T	96,48;145;142	.	.
penA.2.001	penA.2.001	1	1	667	3632	penA	1749	1749	99.09	penA.l6.c30.ctg.1	2212	163.2	0	.	p	.	0	A70T	NONSYN	208	210	GCA	490	492	ACA	169;173;173	A,G;C;A	107,41;151;151	.	.
penA.2.001	penA.2.001	1	1	667	3632	penA	1749	1749	99.09	penA.l6.c30.ctg.1	2212	163.2	0	.	p	.	0	D101E	NONSYN	301	303	GAT	583	585	GAG	196;197;194	G;A;G,T,A	172;173;126,45,1	.	.
penA.2.001	penA.2.001	1	1	667	3632	penA	1749	1749	99.09	penA.l6.c30.ctg.1	2212	163.2	0	.	p	.	0	Y201H	NONSYN	601	603	TAT	883	885	CAT	169;169;171	C,T;A;T	112,45;159;161	.	.
penA.2.001	penA.2.001	1	1	667	3632	penA	1749	1749	99.09	penA.l6.c30.ctg.1	2212	163.2	0	.	p	.	0	Q230K	NONSYN	688	690	CAA	970	972	AAA	190;190;187	A,C;A;A	129,40;172;169	.	.
penA.2.001	penA.2.001	1	1	667	3632	penA	1749	1749	99.09	penA.l6.c30.ctg.1	2212	163.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1213	1215	GCA	193;193;197	G,T;C;A	175,1;172;181	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	667	3632	penA	1749	1749	99.09	penA.l6.c30.ctg.1	2212	163.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1216	1218	ATC	196;194;194	A;T;C	180;180;177	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	667	3632	penA	1749	1749	99.09	penA.l6.c30.ctg.1	2212	163.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1228	1230	GTG	188;187;188	G;T;G	178;176;175	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	667	3632	penA	1749	1749	99.09	penA.l6.c30.ctg.1	2212	163.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1228	1230	GTG	188;187;188	G;T;G	178;176;175	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	667	3632	penA	1749	1749	99.09	penA.l6.c30.ctg.1	2212	163.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1732	1734	ACC	204;204;203	A;C;C	182;184;182	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	667	3632	penA	1749	1749	99.09	penA.l6.c30.ctg.1	2212	163.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1786	1788	GCG	195;197;196	G;C;G	177;164;169	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	667	3632	penA	1749	1749	99.09	penA.l6.c30.ctg.1	2212	163.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1786	1788	GCG	195;197;196	G;C;G	177;164;169	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	667	3632	penA	1749	1749	99.09	penA.l6.c30.ctg.1	2212	163.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1909	1911	GGC	158;157;156	G;G;C	132;131;132	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	667	3632	penA	1749	1749	99.09	penA.l6.c30.ctg.1	2212	163.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1918	1920	GGC	154;152;148	G;G;C	130;128;127	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	667	3632	penA	1749	1749	99.09	penA.l6.c30.ctg.1	2212	163.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1936	1938	CCG	134;136;134	C,G;C;G	106,2;106;103	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	155	5118	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	2981	171.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1516	1518	CCG	206;206;209	C;C,T;G	175;144,38;175	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	659	2104	porA	1146	1146	99.83	porA.l6.c30.ctg.1	1864	112.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	598	598	C	136	C	124	.	.
porA.NCCP11945	porA.NCCP11945	1	0	659	2104	porA	1146	1146	99.83	porA.l6.c30.ctg.1	1864	112.5	0	HET	.	.	.	A64G	.	64	64	A	416	416	A	143	A,G	106,30	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	656	292	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	308	42.7	0	.	p	.	0	V258L	NONSYN	772	774	GTA	94	96	TTA	54;67;67	T,G;T;A	37,10;58;58	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	656	292	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	308	42.7	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	139	141	CAT	81;80;79	C,G;A;T	51,17;67;65	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	656	292	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	308	42.7	0	.	p	.	0	D274S	NONSYN	820	822	GAT	142	144	AGT	79;79;79	A;G;T	66;66;65	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	656	292	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	308	42.7	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	151	153	TAC	73;72;72	T,C;A;C	49,15;64;64	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	656	292	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	308	42.7	0	.	p	.	0	A302V	NONSYN	904	906	GCC	226	228	GTC	22;21;21	G;T,C;C	22;4,17;21	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	656	292	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	308	42.7	0	.	p	.	0	R307E	NONSYN	919	921	AGA	241	243	GAA	19;19;19	G;A;A	18;18;18	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	656	292	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	308	42.7	0	.	p	.	0	T311A	NONSYN	931	933	ACA	253	255	GCA	18;18;18	G;C;A	17;17;18	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	656	292	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	308	42.7	0	.	p	.	0	F314I	NONSYN	940	942	TTC	262	264	ATC	18;17;17	A;T;C	18;17;17	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	656	292	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	308	42.7	0	.	p	.	0	A316S	NONSYN	946	948	GCG	268	270	TCG	17;17;17	T;C;G	16;17;17	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	656	292	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	308	42.7	0	.	p	.	0	V318A	NONSYN	952	954	GTC	274	276	GCC	16;16;16	G;C;C	16;16;15	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	656	292	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	308	42.7	0	.	p	.	0	G319S	NONSYN	955	957	GGC	277	279	AGC	16;15;15	A;G;C	15;14;14	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	656	292	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	308	42.7	0	.	p	.	0	G320A	NONSYN	958	960	GGT	280	282	GCC	15;16;16	G;C;C	15;16;16	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	656	292	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	308	42.7	0	.	p	.	0	G322V	NONSYN	964	966	GGT	286	288	GTT	14;14;14	G;T;T	14;14;13	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	.	p	.	0	T87A	NONSYN	259	261	ACT	582	584	GCT	211;214;216	G,A;C;T	146,38;188;188	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	.	p	.	0	.	INDELS	629	630	AA	953	955	TAG	171;167;169	T;A;G	157;157;128	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	.	p	.	0	.	MULTIPLE	631	633	TAC	957	960	CAAT	176;176;178;179	C;A;A;T,G	164;164;167;129,37	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	.	p	.	0	N212fs	FSHIFT	634	634	A	962	962	T	181	T	170	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	1	SNP	p	G120K	0	.	.	358	360	GGT	681	683	GGT	194;193;188	G;G;T,C,G	175;174;136,30,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	1	SNP	p	A121D	0	.	.	361	363	GCC	684	686	GCC	190;188;187	G;C;C	171;172;171	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	1	SNP	p	A121N	0	.	.	361	363	GCC	684	686	GCC	190;188;187	G;C;C	171;172;171	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	T63C	.	63	63	T	386	386	T	209	T,C	142,44	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	T192C,A	.	192	192	T	515	515	T	212	T,C,A	144,40,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	C452T	.	452	452	C	775	775	C	214	C,T	163,28	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	T326C	.	326	326	T	649	649	T	189	T,C	136,29	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	C330T	.	330	330	C	653	653	C	195	C,T	145,32	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	C486T	.	486	486	C	809	809	C	203	C,T	153,33	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	C492T	.	492	492	C	815	815	C	196	C,T	147,31	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	C118A	.	118	118	C	441	441	C	200	C,A	149,36	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	G119C	.	119	119	G	442	442	G	199	G,C	147,35	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	G120A	.	120	120	G	443	443	G	200	G,A	144,37	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	A129G	.	129	129	A	452	452	A	198	A,G	140,31	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	T513C	.	513	513	T	836	836	T	195	T,C	146,33	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	G133A,T	.	133	133	G	456	456	G	191	G,A,T	136,28,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	T134G	.	134	134	T	457	457	T	190	T,G	137,29	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	G136A	.	136	136	G	459	459	G	185	G,A	134,30	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	G137A	.	137	137	G	460	460	G	184	G,A	133,29	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	C138A	.	138	138	C	461	461	C	183	C,A	131,28	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	A392T	.	392	392	A	715	715	A	206	A,T	152,34	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	G400A	.	400	400	G	723	723	G	199	G,A	153,25	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	G402T	.	402	402	G	725	725	G	199	G,T	154,26	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	T403G	.	403	403	T	726	726	T	197	T,G	150,25	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	T405G	.	405	405	T	728	728	T	199	T,G	154,26	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	T160G	.	160	160	T	483	483	T	211	T,G	134,45	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	A418G	.	418	418	A	741	741	A	195	A,G	144,28	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	A419G	.	419	419	A	742	742	A	195	A,G	144,28	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	A427C	.	427	427	A	750	750	A	196	A,C	150,28	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	G428A	.	428	428	G	751	751	G	197	G,A	153,28	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	A303G	.	303	303	A	626	626	A	190	A,G	137,32	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	G48A	.	48	48	G	371	371	G	204	G,A	141,42	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	G560A	.	560	560	G	883	883	G	180	G,A	129,34	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	G565A	.	565	565	G	888	888	G	179	G,A	130,34	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	2452	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1488	162.0	0	HET	.	.	.	C315T	.	315	315	C	638	638	C	192	C,T	138,30	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	155	9528	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4731	200.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1969	1971	AAT	200;207;211	A,C;A;T	135,50;187;192	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1086	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1173	92.4	1	SNP	p	V57M	1	.	.	169	171	ATG	601	603	ATG	230;231;230	A;T;G	203;205;203	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
tetM.WHO_G_pTetM_00047	tetM.WHO_G_pTetM_00047	1	0	27	2510	tetM	1920	1920	100.0	tetM.l15.c4.ctg.1	2541	98.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Tetracycline resistance
